Veeva Funding: How Much Did They Raise & Key Investors

How Much Did Veeva Raise?
Funding & Key Investors

Veeva has solidified its position as a cornerstone of the life sciences technology ecosystem, having secured a cumulative total of $258M in capital throughout its operational history. The firm recently finalized a major strategic investment of $35M, marking a significant milestone in its trajectory toward dominating the enterprise cloud software market. This influx of financing underscores the market's confidence in Veeva's ability to scale its integrated industry cloud solutions, which are increasingly vital for global pharmaceutical and biotechnology entities navigating complex regulatory landscapes.

The company's growth narrative is characterized by a disciplined approach to capital allocation, transitioning from early-stage venture backing to substantial public market offerings. By maintaining a focus on high-value, mission-critical software, Veeva has successfully navigated multiple funding cycles, ensuring it remains at the forefront of digital transformation within the healthcare sector.

What is Veeva?

Veeva

Software

Customer Engagement Platforms

Veeva operates as a premier provider of cloud-based software, data, artificial intelligence, and business consulting solutions tailored specifically for the life sciences industry. Its integrated industry cloud platform serves as a foundational architecture for pharmaceutical, biotechnology, and medical device organizations. By streamlining research and development, managing intricate regulatory processes, and optimizing engagement with healthcare professionals, Veeva enables its clients to accelerate the delivery of life-saving therapies to patients worldwide. The company's market position is defined by its deep domain expertise and its ability to provide a unified, scalable infrastructure that addresses the unique compliance and operational challenges inherent in the life sciences sector.

How much funding has Veeva raised?

Veeva has raised a total of $258M across 4 funding rounds:

2007

Series A

$3M

2008

Series B

$4M

2013

Stock Offering

$216M

2014

Stock Offering

$35M

Series A (2007): $3M with participation from Undisclosed

Series B (2008): $4M led by Emergence Capital Partners

Stock Issuance/Offering (2013): $216M supported by Undisclosed

Stock Issuance/Offering (2014): $35M featuring Undisclosed

Key Investors in Veeva

Emergence Capital Partners

Emergence is a prominent venture capital firm specializing in early-stage enterprise software companies, with a focus on identifying and scaling platforms that fundamentally transform global work processes.

Undisclosed Investors

What's next for Veeva?

Looking ahead, Veeva is well-positioned to leverage its recent capital infusion to further expand its artificial intelligence capabilities and deepen its footprint in emerging biotech markets. As the life sciences industry continues to prioritize data-driven decision-making and digital agility, Veeva's strategic roadmap likely involves enhancing its suite of regulatory and commercial solutions to meet evolving global standards. The company's focus on maintaining its enterprise-level dominance suggests a continued commitment to R&D investment and potential strategic acquisitions that complement its existing cloud ecosystem. By bridging the gap between complex clinical research and commercial execution, Veeva remains a critical partner for organizations striving to improve patient outcomes through technological innovation.

See full Veeva company page

See More Financial Insights